Adjusting diet with @entity8083 in XXXX : what factors should be considered?

@entity1 @entity8083 @entity28 @entity8084 @entity814 @entity74 @entity3147 @entity815
The usual treatment for @entity814 ( @entity814 ) is a @entity815 -restricted diet. Following this diet is challenging, and long-term adherence (and hence metabolic control) is commonly poor. @entity1 with @entity814 (usually, but not exclusively, with a relatively mild @entity74 ) who are responsive to treatment with pharmacological doses of @entity8083 (BH4) have either lower concentrations of blood @entity815 or improved dietary @entity815 tolerance. The availability of a registered formulation of @entity8084 ( @entity8083 , @entity8083  ) has raised many practical issues and new questions in the dietary management of these @entity1 . Initially, @entity1 and carers must understand clearly the likely benefits (and limitations) of @entity8083 therapy. A minority of @entity1 who respond to @entity8083 are able to discontinue the @entity815 -restricted diet completely, while others are able to relax the diet to some extent. Care is required when altering the @entity815 -restricted diet, as this may have unintended nutritional consequences and must be undertaken with caution. New clinical protocols are required for managing any dietary change while maintaining control of blood @entity815 , ensuring adequate nutrition and preventing @entity3147 , overweight or @entity28 . An accurate initial evaluation of pre- @entity8083 @entity815 tolerance is essential, and the desired outcome from treatment with @entity8083 (e.g. reduction in blood @entity815 or relaxation in diet) must also be understood by the @entity1 and carers from the outset. Continuing education and support will be required thereafter, with further adjustment of diet and @entity8083 dosage as a young @entity1 grows.
